Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Bright Minds Biosciences Inc (DRUG.CN)

Bright Minds Biosciences Inc (DRUG.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Bright Minds Biosciences Inc 19 Vestry Street New York NY 10013 USA

https://www.brightmindsbio.com P: 647-865-8622

Description:

Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Key Statistics

Overview:

Market Capitalization, $K 7,365
Shares Outstanding, K 4,464
Annual Sales, $ 0 K
Annual Net Income, $ -7,372 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -1,684 K
60-Month Beta 1.71
% of Institutional Shareholders 3.94%

Growth:

1-Year Return -45.00%
3-Year Return -95.65%
5-Year Return 0.00%

Per-Share Information:

Latest Earnings Date N/A
Earnings Per Share ttm -1.77
EPS Growth vs. Prev Year -61.72%
Dividend Payout Ratio 0.00%
Most Recent Split 1-5 on 07/14/23

DRUG.CN Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -79.07%
Return-on-Assets % -72.91%
Profit Margin % 0.00%
Debt/Equity N/A
Price/Sales N/A
Price/Book 1.22
Book Value/Share 1.35
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar